Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Mirati Therapeutics, Inc. (MRTX)
|
|
| Balance Sheet |
|
|
|
| Standardized | As Reported |
Annual | Quarterly |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| ASSETS | | | | | | | | |
| Current assets | | | | | | | | |
| Cash and cash equivalents | 129.9 | 241.9 | 235.3 | 298.8 | 265.6 | 304.7 | 413.1 | 242.6 |
| Short-term investments | 649.6 | 660.4 | 848.6 | 902.1 | 915.7 | 1,021.8 | 1,078.3 | 911.8 |
| Accounts receivable, net | 10.5 | 6.2 | 0.9 | | | | | |
| Inventory | 8.6 | 3.8 | 3.0 | | | | | |
| Other current assets | 20.3 | 27.0 | 21.2 | 24.8 | 21.6 | 16.6 | 16.6 | 17.5 |
| Total current assets | 818.9 | 939.4 | 1,109.0 | 1,225.8 | 1,202.9 | 1,343.1 | 1,508.0 | 1,171.9 |
| Property and equipment, net | 16.9 | 17.2 | 17.5 | 17.9 | 17.2 | 17.2 | 15.8 | 13.7 |
| Intangible asset, net | 14.4 | 14.7 | 14.9 | | | | | |
| Long-term investment | 4.6 | 3.4 | 3.5 | 1.9 | 2.6 | 3.1 | 8.2 | 11.3 |
| Right-of-use asset | 35.4 | 35.8 | 36.1 | 36.5 | 36.8 | 37.2 | 37.7 | 38.2 |
| Other long-term assets | 24.9 | 23.4 | 21.6 | 21.1 | 20.2 | 20.6 | 19.0 | 18.4 |
| Total assets | 915.0 | 1,033.8 | 1,202.6 | 1,303.1 | 1,279.8 | 1,421.3 | 1,588.8 | 1,253.4 |
| |
| LIABILITIES AND SHAREHOLDERS' EQUITY | | | | | | | | |
| Current liabilities | | | | | | | | |
| Accounts payable | 32.5 | 22.3 | 38.9 | 19.5 | 24.3 | 27.9 | 35.2 | 42.9 |
| Accrued liabilities | 107.5 | 102.3 | 120.6 | 107.5 | 94.9 | 95.6 | 108.5 | 79.2 |
| Total current liabilities | 140.0 | 124.6 | 159.4 | 127.0 | 119.1 | 123.6 | 143.7 | 122.1 |
| Lease liability | 42.7 | 43.2 | 43.7 | 44.1 | 45.8 | 45.8 | | 45.5 |
| Other liabilities | 3.4 | 3.3 | 3.0 | 3.0 | 2.8 | 2.6 | 2.2 | 1.8 |
| Total liabilities | 186.1 | 171.1 | 206.1 | 174.0 | 167.8 | 172.0 | 191.7 | 169.4 |
| |
| Commitments and contingencies (see Note 11) | | | | | | | | |
| Shareholders' equity | | | | | | | | |
| Common stock | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Additional paid-in capital | 3,545.0 | 3,501.8 | 3,453.1 | 3,385.5 | 3,185.4 | 3,145.4 | 3,099.9 | 2,586.8 |
| Accumulated other comprehensive loss | -1.7 | -1.7 | -3.7 | -6.1 | 3.4 | 4.3 | 9.1 | 9.6 |
| Accumulated deficit | -2,814.4 | -2,637.5 | -2,452.9 | -2,250.4 | -2,076.9 | -1,900.4 | -1,712.0 | -1,512.4 |
| Total shareholders' equity | 729.0 | 862.6 | 996.5 | 1,129.1 | 1,112.0 | 1,249.3 | 1,397.0 | 1,084.0 |
| Total liabilities and shareholders' equity | 915.0 | 1,033.8 | 1,202.6 | 1,303.1 | 1,279.8 | 1,421.3 | 1,588.8 | 1,253.4 |
|